Im Hyung-Jun, Yoon Hai-Jeon, Lee Eun Seong, Kim Tae-Sung, Kim Joo-Young, Chung June-Key, Kim Seok-ki, Park Sang-Yoon
aDepartment of Nuclear Medicine bCenter for Uterine Cancer, National Cancer Center, Goyang-Si cDepartment of Nuclear Medicine, Seoul National University College of Medicine, Seoul dDepartment of Molecular Medicine and Biopharmaceutical Sciences, WCU Graduate School of Convergence Science and Technology, Seoul National University, Yeongeon-Dong, Korea.
Nucl Med Commun. 2014 Mar;35(3):268-75. doi: 10.1097/MNM.0000000000000037.
Lymph node involvement in cervical cancer is an indication of poor prognosis and the risk tends to increase according to the level of lymph node involvement. However, the specific prognostic significance of retrocrural lymph node involvement has not been well characterized because of its small size and deep location. The aim of this study was to assess its prognostic value.
A total of 217 patients with newly diagnosed International Federation of Gynecology and Obstetrics (FIGO) stage IA2-IVA cervical cancer were retrospectively enrolled. All the patients had undergone pretreatment (18)F-fluorodeoxy-D-glucose ((18)F-FDG) PET/CT. Of these patients 145 were treated with concurrent chemoradiotherapy, and in this group we assessed the relationship of retrocrural lymph node involvement with the risk of disease progression.
Retrocrural lymph node involvement was seen in 7.4% of patients (16/217). All of them had para-aortic lymph node involvement and 56% of the 16 patients (9/16) had concomitant supraclavicular lymph node involvement. In the patients treated with concurrent chemoradiotherapy it was found that the higher the level of (18)F-FDG-positive lymph nodes detected in them, the worse the progression-free survival experienced by them (none vs. pelvic, pelvic vs. para-aortic, para-aortic vs. retrocrural; P<0.05); however, there was no difference in progression outcome between retrocrural and supraclavicular areas (P=NS). On multivariate Cox proportional hazard analysis, the highest level of (18)F-FDG PET/CT-positive lymph nodes in the para-aortic [hazard ratio (HR) 6.05, 95% confidence interval (CI) 2.18-16.81], retrocrural (HR 17.05, 95% CI 5.34-54.44), and supraclavicular areas (HR 19.56, 95% CI 7.15-53.54) was a significant prognostic factor.
The highest level of lymph node involvement in para-aortic, retrocrural, supraclavicular areas was a significant prognostic factor for progression in uterine cervical cancer patients who were treated with concurrent chemoradiotherapy. Retrocrural lymph node involvement shows a similar outcome with supraclavicular involvement, but leads to a worse outcome in terms of progression compared with para-aortic lymph node involvement.
宫颈癌患者出现淋巴结转移提示预后不良,且预后风险往往随着淋巴结转移水平的升高而增加。然而,由于膈脚后淋巴结体积小且位置深,其具体的预后意义尚未得到充分阐明。本研究旨在评估其预后价值。
本研究回顾性纳入了217例新诊断为国际妇产科联盟(FIGO)IA2-IVA期宫颈癌的患者。所有患者均接受了治疗前的(18)F-氟脱氧-D-葡萄糖((18)F-FDG)PET/CT检查。其中145例患者接受了同步放化疗,在该组患者中,我们评估了膈脚后淋巴结转移与疾病进展风险之间的关系。
7.4%(16/217)的患者出现了膈脚后淋巴结转移。所有患者均有腹主动脉旁淋巴结转移,16例患者中有56%(9/16)同时伴有锁骨上淋巴结转移。在接受同步放化疗的患者中,发现检测到的(18)F-FDG阳性淋巴结水平越高,其无进展生存期越差(无转移vs.盆腔转移、盆腔转移vs.腹主动脉旁转移、腹主动脉旁转移vs.膈脚后转移;P<0.05);然而,膈脚后和锁骨上区域之间的进展结果没有差异(P=无显著性差异)。多因素Cox比例风险分析显示,腹主动脉旁[风险比(HR)6.05,95%置信区间(CI)2.18-16.81]、膈脚后(HR 17.05,95%CI 5.34-54.44)和锁骨上区域(HR 19.56,95%CI 7.15-53.54)的(18)F-FDG PET/CT阳性淋巴结最高水平是一个显著的预后因素。
腹主动脉旁、膈脚后、锁骨上区域的最高淋巴结转移水平是接受同步放化疗的宫颈癌患者疾病进展的显著预后因素。膈脚后淋巴结转移与锁骨上淋巴结转移的结果相似,但与腹主动脉旁淋巴结转移相比,其在疾病进展方面的预后更差。